BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

On Friday, BridgeBio Pharma, Inc. BBIO presented a post-hoc analysis evaluating the effect of acoramidis on the composite endpoint of all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) events in its Phase 3 ATTRibute-CM study in ATTR-CM.The data were shared at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024.Also Read: BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition.ATTRibute-CM was designed to evaluate the efficacy ...